Research programme: cytokine-based immunotherapeutics - Intrexon

Drug Profile

Research programme: cytokine-based immunotherapeutics - Intrexon

Alternative Names: Research programme: cytokine-based immunotherapeutics - Intrexon/ZIOPHARM

Latest Information Update: 09 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Intrexon Corporation; ZIOPHARM Oncology
  • Class Cell therapies; Interleukins; T lymphocyte cell therapies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Research Graft-versus-host disease

Most Recent Events

  • 31 Dec 2017 ZIOPHARM Oncology terminates its licence for cytokine based immunotherapeutics for Graft versus host disease
  • 29 Sep 2015 Intrexon and ZIOPHARM Oncology agree to co-develop cytokine-based immunotherapeutics in USA for Graft-versus-host disease
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top